Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia

Cell Stem Cell

Volumn 20, Issue 3, 2017, Pages 315-328.e7

  Kotini, Andriana G ^a   Chang, Chan Jung ^a   Chow, Arthur ^b   Yuan, Han ^b   Ho, Tzu Chieh ^b   Wang, Tiansu ^a   Vora, Shailee ^a   Solovyov, Alexander ^a   Husser, Chrystel ^a   Olszewska, Malgorzata ^a   Teruya Feldstein, Julie ^a   Perumal, Deepak ^a   Klimek, Virginia M ^b   Spyridonidis, Alexandros ^c   Rampal, Raajit K ^b   Silverman, Lewis ^a   Reddy, E Premkumar ^a   Papaemmanuil, Elli ^b   Parekh, Samir ^a   Greenbaum, Benjamin D ^a   Leslie, Christina S ^b   Kharas, Michael G ^b   Papapetrou, Eirini P ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

acute myeloid leukemia; cancer progression; hPSC derived hematopoiesis; induced pluripotent stem cells; iPSC disease modeling; leukemia; leukemia progression; myelodysplastic syndrome; myeloid malignancy; transplantation

Indexed keywords

AZACITIDINE; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTOME; ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DNA METHYLATION; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOPOIETIC CELL; INDUCED PLURIPOTENT STEM CELL; MOUSE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRELEUKEMIA; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELL TRANSFORMATION; CYTOLOGY; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA, MYELOID, ACUTE; MICE; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; NEOPLASM TRANSPLANTATION; PHENOTYPE; TRANSCRIPTOME;

EID: 85012921656     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2017.01.009     Document Type: Article

References (48)

1. Akalin, A., Garrett-Bakelman, F.E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Milne, T.A., Huang, Y., Biswas, D., Hess, J.L., et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet., 8, 2012, e1002781.
2. Akalin, A., Kormaksson, M., Li, S., Garrett-Bakelman, F.E., Figueroa, M.E., Melnick, A., Mason, C.E., methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol., 13, 2012, R87.
3. Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., Vardiman, J.W., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 (2016), 2391–2405.
4. Athuluri-Divakar, S.K., Vasquez-Del Carpio, R., Dutta, K., Baker, S.J., Cosenza, S.C., Basu, I., Gupta, Y.K., Reddy, M.V., Ueno, L., Hart, J.R., et al. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 165 (2016), 643–655.
5. Bejar, R., Steensma, D.P., Recent developments in myelodysplastic syndromes. Blood 124 (2014), 2793–2803.
6. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
7. Collin, M., Dickinson, R., Bigley, V., Haematopoietic and immune defects associated with GATA2 mutation. Br. J. Haematol. 169 (2015), 173–187.
8. de Pater, E., Kaimakis, P., Vink, C.S., Yokomizo, T., Yamada-Inagawa, T., van der Linden, R., Kartalaei, P.S., Camper, S.A., Speck, N., Dzierzak, E., Gata2 is required for HSC generation and survival. J. Exp. Med. 210 (2013), 2843–2850.
9. Elias, H.K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A., Steidl, U., Stem cell origin of myelodysplastic syndromes. Oncogene 33 (2014), 5139–5150.
10. Flores-Figueroa, E., Gutiérrez-Espindola, G., Guerrero-Rivera, S., Pizzuto-Chavez, J., Mayani, H., Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk. Res. 23 (1999), 385–394.
11. Genovese, G., Kähler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371 (2014), 2477–2487.
12. Gilliland, D.G., Griffin, J.D., The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002), 1532–1542.
13. Gilliland, D.G., Tallman, M.S., Focus on acute leukemias. Cancer Cell 1 (2002), 417–420.
14. Hahn, C.N., Chong, C.E., Carmichael, C.L., Wilkins, E.J., Brautigan, P.J., Li, X.C., Babic, M., Lin, M., Carmagnac, A., Lee, Y.K., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43 (2011), 1012–1017.
15. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burtt, N., Chavez, A., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371 (2014), 2488–2498.
16. Jan, M., Snyder, T.M., Corces-Zimmerman, M.R., Vyas, P., Weissman, I.L., Quake, S.R., Majeti, R., Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med., 4, 2012, 149ra118.
17. Kerbauy, D.B., Deeg, H.J., Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp. Hematol. 35 (2007), 1739–1746.
18. Kim, J., Zaret, K.S., Reprogramming of human cancer cells to pluripotency for models of cancer progression. EMBO J. 34 (2015), 739–747.
19. Kim, J., Hoffman, J.P., Alpaugh, R.K., Rhim, A.D., Reichert, M., Stanger, B.Z., Furth, E.E., Sepulveda, A.R., Yuan, C.X., Won, K.J., et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 3 (2013), 2088–2099.
20. Kotini, A.G., Chang, C.J., Boussaad, I., Delrow, J.J., Dolezal, E.K., Nagulapally, A.B., Perna, F., Fishbein, G.A., Klimek, V.M., Hawkins, R.D., et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat. Biotechnol. 33 (2015), 646–655.
21. Link, D.C., Walter, M.J., ‘CHIP'ping away at clonal hematopoiesis. Leukemia 30 (2016), 1633–1635.
22. Martincorena, I., Campbell, P.J., Somatic mutation in cancer and normal cells. Science 349 (2015), 1483–1489.
23. Ng, E.S., Davis, R., Stanley, E.G., Elefanty, A.G., A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies. Nat. Protoc. 3 (2008), 768–776.
24. Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O.I., Wilson, G., Kaufmann, K.B., McLeod, J., Laurenti, E., Dunant, C.F., et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science, 351, 2016, aab2116.
25. Pandolfi, A., Barreyro, L., Steidl, U., Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl. Med. 2 (2013), 143–150.
26. Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Yoon, C.J., Ellis, P., Wedge, D.C., Pellagatti, A., et al., Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122 (2013), 3616–3627 quiz 3699.
27. Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., Potter, N.E., Heuser, M., Thol, F., Bolli, N., et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374 (2016), 2209–2221.
28. Papapetrou, E.P., Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat. Med. 22 (2016), 1392–1401.
29. Papapetrou, E.P., Sadelain, M., Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nat. Protoc. 6 (2011), 1251–1273.
30. Papapetrou, E.P., Tomishima, M.J., Chambers, S.M., Mica, Y., Reed, E., Menon, J., Tabar, V., Mo, Q., Studer, L., Sadelain, M., Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc. Natl. Acad. Sci. USA 106 (2009), 12759–12764.
31. Papapetrou, E.P., Lee, G., Malani, N., Setty, M., Riviere, I., Tirunagari, L.M., Kadota, K., Roth, S.L., Giardina, P., Viale, A., et al. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat. Biotechnol. 29 (2011), 73–78.
32. Pellagatti, A., Cazzola, M., Giagounidis, A., Perry, J., Malcovati, L., Della Porta, M.G., Jädersten, M., Killick, S., Verma, A., Norbury, C.J., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24 (2010), 756–764.
33. Sanjuan-Pla, A., Macaulay, I.C., Jensen, C.T., Woll, P.S., Luis, T.C., Mead, A., Moore, S., Carella, C., Matsuoka, S., Bouriez Jones, T., et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 502 (2013), 232–236.
34. Sato, T., Kim, S., Selleri, C., Young, N.S., Maciejewski, J.P., Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia 12 (1998), 1187–1194.
35. Shlush, L.I., Zandi, S., Mitchell, A., Chen, W.C., Brandwein, J.M., Gupta, V., Kennedy, J.A., Schimmer, A.D., Schuh, A.C., Yee, K.W., et al., HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506 (2014), 328–333.
36. Sperling, A.S., Gibson, C.J., Ebert, B.L., The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat. Rev. Cancer 17 (2017), 5–19.
37. Steensma, D.P., Bejar, R., Jaiswal, S., Lindsley, R.C., Sekeres, M.A., Hasserjian, R.P., Ebert, B.L., Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.
38. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
39. Themeli, M., Kloss, C.C., Ciriello, G., Fedorov, V.D., Perna, F., Gonen, M., Sadelain, M., Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31 (2013), 928–933.
40. Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Löwenberg, B., Delwel, R., Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004), 1617–1628.
41. Vo, L.T., Daley, G.Q., De novo generation of HSCs from somatic and pluripotent stem cell sources. Blood 125 (2015), 2641–2648.
42. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366 (2012), 1090–1098.
43. Walter, M.J., Shen, D., Shao, J., Ding, L., White, B.S., Kandoth, C., Miller, C.A., Niu, B., McLellan, M.D., Dees, N.D., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27 (2013), 1275–1282.
44. Will, B., Zhou, L., Vogler, T.O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y., Bhagat, T.D., Bhattacharyya, S., Barreyro, L., et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 120 (2012), 2076–2086.
45. Wlodarski, M.W., Hirabayashi, S., Pastor, V., Starý, J., Hasle, H., Masetti, R., Dworzak, M., Schmugge, M., van den Heuvel-Eibrink, M., Ussowicz, M., et al., EWOG-MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 127 (2016), 1387–1397 quiz 1518.
46. Woll, P.S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D.C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 25 (2014), 794–808.
47. Woolthuis, C.M., Park, C.Y., Hematopoietic stem/progenitor cell commitment to the megakaryocyte lineage. Blood 127 (2016), 1242–1248.
48. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20 (2014), 1472–1478.